Development of a Prophylactic Butyrylcholinesterase Bioscavenger to Protect Against Insecticide Toxicity Using a Homologous Macaque Model by Yvonne Rosenberg et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Development of a Prophylactic 
Butyrylcholinesterase Bioscavenger to Protect 
Against Insecticide Toxicity Using a 
Homologous Macaque Model 
Yvonne Rosenberg, Xiaoming Jiang, Lingjun Mao,  
Segundo Hernandez Abanto, Keunmyoung Lee 
PlantVax Inc.  
USA 
1. Introduction 
Organophosphorus (OP) and carbamate pesticides are extensively used to control 
agricultural, household and structural pests. Each year approximately 5.6 billion pounds of 
pesticides are used worldwide potentially exposing ~1.8 billion people who use pesticides to 
protect the food and commercial products that they produce (Alavanja, 2009). Although 
unintentional occupational poisonings represent only a small number, estimated to be ~10% 
(Litchfield, 2005) or 25 million agricultural workers globally (Jeyaratnam, 1990), large scale 
exposure of both civilian and military personnel has become an ever increasing threat, as a 
result of deliberate insecticide contamination of the environment and critical water supplies  
by terrorists. In this context, pesticide use is one of only two exposures consistently 
identified by Gulf War epidemiologic studies to be significantly associated with the 
multisymptom illness profiles described as Gulf War illness (Cao et al., 2011). Pesticide use 
has also been associated with neurocognitive deficits and neuroendocrine alterations in Gulf 
War veterans in clinical studies conducted following the end of the war.  
While OP nerve agents and WHO Class I and Class II OP pesticides constitute a diverse 
group of chemical structures, all potentially exhibit a common mechanism of toxicity, that is, 
active site phosphorylation of acetylcholine (AChE) resulting in AChE inhibition and 
accumulation of acetylcholine, overstimulation of cholinergic receptors, and consequent 
clinical signs of cholinergic toxicity such as seizures, brain damage and cognitive and 
behavioural defects (Millard et al., 1999; Rosenberry et al., 1999; Colosio et al., 2009). The 
relationship between AChE inhibition and symptoms showed that prevalence ratios were 
significantly >1 for respiratory, eye and central nervous system symptoms for workers with 
>30% inhibition (Ohayo-Mitoko et al., 2000). More recent studies indicate that insecticide 
exposure to DFP (diisopropyl fluorophosphate) causes a prolonged increased in 
hippocampal neuronal Ca++ plateau which may underlie morbidity and mortality 
(Deshpande et al., 2010). These findings are consistent with those indicating persistent 
changes in locus coeruleus noradrenergic neuronal activity and lasting changes in this brain 
area after removal of the insecticide chlorpyrifos oxon; reminiscent of the lasting cognitive 
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symptoms of Gulf War illness in soldiers exposed to these compounds (US DOD, Pesticides-
Final Report, 2003).  
Currently, the standard (approved) treatment for acute OP pesticide poisoning involves 
administration of intravenous (iv) atropine and an oxime e.g. obidoxime, pralidoxime to 
reactivate inhibited AChE (Worek et al., 2010). However, the effectiveness and safety of 
oxime administration in acute OP pesticide-poisoned patients has been challenged and a 
recent clinical trial showed no clinical benefits and a trend towards harm in all sub-groups, 
despite clear evidence that these doses reactivated AChE in the blood (Buckley et al., 2011).  
An efficacious prophylactic therapeutic treatment for preventing insecticide poisoning that 
can bind and scavenge the OP before it reaches and targets AChE in neuromuscular 
junctions is therefore a high priority. The leading candidate of this type is native (plasma) 
butyrylcholinesterase (BChE) whose potent OP bioscavenging ability has been 
demonstrated in many animal models and against varied OP neurotoxins (Doctor et al., 
2001; Lenz et al., 2001). While several new catalytic and other stoichiometric enzymes also 
exhibit this ability (Lenz et al., 2007), based on availability, broad spectrum efficacy, stability 
and safety (Sun et al., 2005), BChE is the most advanced in terms of development of a 
human treatment. In Turkey, frozen plasma (BChE levels of 3,000 - 5,700 units) given as an 
alternative or adjunctive treatment with atropine and oximes, has been shown to prevent 
mortality and intermediate syndrome in acutely insecticide-exposed and hospitalized 
individuals (Güven et al., 2004). Currently, BChE also finds use as a treatment of cocaine 
overdose and for the alleviation of succinylcholine-induced apnea. 
Structurally, BChE (also known as pseudocholinesterase or non-specific cholinesterase) is a 
serine esterase (MW=345,000) comprised of four identical subunits each containing 574 
amino acids, held together by non-covalent bonds, with 36 carbohyrdrate chains (23.9% by 
weight) (Lockridge, 1990; Nachon et al., 2002). BChE is found in all species at levels of 1-20 
ug/ml in plasma (Rosenberg, unp. data) and is also abundant in liver, intestine and lung. 
Recombinant (r) human butyryl-cholinesterase (HuBChE), like the native form, is also a 
potent bioscavenger of OP neurotoxins (Doctor et al., 2001; Lenz et al., 2001; Raveh et al., 
1997) but its development as a human treatment for pesticide exposure has been 
disadvantaged by: (i) poor in vivo stability (bioavailability) of the unmodified forms and the 
presence of potentially immunogenic glycans using certain expression systems (ii) a 1:1 
stoichiometry between the enzyme and OP (Raveh et al., 1997) and (iii) the high LD50 of 
insecticides (ug-mg/kg levels). This necessitates the delivery of large, costly, rBChE doses to 
detoxify exposed individuals which is problematic when intramuscular (im) or 
subcutaneous (sc) injections are the chosen routes of delivery. In this chapter, we shall 
describe our experience of how the chemistry, glycosylation, chemical modification, animal 
model and route of administration may reduce or enhance the potential of BChE 
bioscavengers as prophylactic therapeutic human antidotes for OP insecticide exposure.  
2. Production of tetrameric and monomeric forms of rMaBChE and rHuBChE  
Macaque (Ma) and human (Hu) BChE molecules are very similar molecules differing by 
only 22 amino acids and sharing ~96% DNA sequence identity, critical glycosylation sites, 
cysteines and disulfide bridging (Boeck et al., 2002; Rosenberg et al., 2010). Thus, most anti-
BChE antisera react with both molecules. Native HuBChE and MaBChE in plasma are 
composed predominantly of tetramers (98%) with the tetramerization domain being located 
within the last 40 C-terminal residues of each monomeric subunit (534-574) (Blong et al., 
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1997). In human serum, the association of lamellipodin proline rich peptides with the 
monomeric chains results in the formation of BChE tetramers (Li et al., 2008). Recombinant 
BChE produced in mammalian cells, in contrast, has only 10-20% tetrameric forms and 
therefore optimal tetramerization requires the addition of either poly(L-proline) to the 
culture medium or co-expression of the full length BChE monomers with the proline-rich 
attachment domain (PRAD) of ColQ gene (Altamirano & Lockridge, 1999). 
To date, rHuBChE and rMaBChE molecules have been produced in transgenic mammalian 
cells (Chilukuri et al., 2008; Rosenberg et al, 2010), goat milk (Huang et al., 2007) and in 
plants (Geyer et al., 2010; Jiang, unpub. data). Our approach has been to utilize two 
expression systems for the production of rMaBChE and rHuBChE. Initially, Chinese 
hamster ovary cells (CHO) were used because of their human-like glycosylation. More 
recently, a transient plant expression platform was adopted to increase the yield and reduce 
the time and cost of producing rBChE. Although CHO cells and plants are able to produce 
significant levels of tetrameric BChE molecules (Li et al., 2008; Geyer et al., 2010), in the 
present studies, co-transfection of the BChE and PRAD genes has been shown to increase 
both levels of tetramerization and yields in each expression system. While the CHO cell 
expression of recombinant proteins is very well established, recent innovations in transient 
plant expression systems e.g. Bayer’s Magnifection system (Gleba  et al., 2005) and the Cow 
Pea Mosaic Virus Hyper-translatable Protein Expression System (PBL Technology) 
(Sainsbury et al., 2008) have been shown to be some of the most rapid, cost effective and 
productive expression systems in existence; capable of producing grams of recombinant 
proteins in weeks (Goodin et al., 2008).  
 
CHO-derived (Stable Transfection)* Plant-derived (Transient Transfection)* 
rMaBChE#+ rHuBChE rMaBChE# 
    N. tobacum N. benthamiana 
Monomeric Tetrameric Monomeric Tetrameric Monomeric Tetrameric Tetrameric 
8U/ml 
(9mg/L) 
25U/ml 
(28mg/L) 
16 U/ml 
(22.9mg/L) 
45 U/ml 
(64.3 mg/L) 
60 U/gm 
(66.6 mg/kg) 
140 U/gm 
(155.5 mg/kg) 
400 U/gm 
(444 mg/kg) 
*All tobacco plants and leaves from Nicotiana tobacum and N. benthamiana were transfected using 
Agrobacterium-mediated infiltration   
# CHO supernatants and whole leaf extracts are prepared for purification.  
+ BChE activity is determined spectrophotometrically (Grunwald at al., 1997), using butyrylthiocholine 
(BTC) (0.5 mM each) as substrate. One unit of enzyme activity is the amount required to hydrolyze 1 
umol substrate/min. One mg MaBChE has 900 units of activity and one mg HuBChE has 700units. 
Table 1. Expression levels of different forms of rBChE using CHO-and plant-based 
expression systems.  
In addition to the tetrameric forms, a truncated monomeric form of rBChE (MW=~81KDa) 
that is incapable of oligomerization has also been produced by the insertion of a stop codon 
at G534 resulting in a monomeric form lacking 41 C-terminal residues (Blong et al., 1997). 
The smaller monomeric molecules may more rapidly gain access to the blood from muscle 
or lungs (depending on the route of delivery) with transiently higher bioavailablity in the 
plasma, which would be advantageous in emergency situations that require real time 
responses and rapid treatment or booster administrations.  
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3. In vitro biological properties of rMaBChE 
To test the chemical properties of CHO- and tobacco-derived rMaBChE, inhibition and 
reactivation assays using  diisopropyl fluorophosphate (DFP) and paraoxon (diethyl 4-
nitrophenyl phosphate) have been performed with and without the oxime 2-PAM (pyridine-
2-aldoxime methochloride)(Luo et al., 2008). DFP is an OP compound that has been used as 
an experimental insecticide agent in neuroscience because of its ability to inhibit 
cholinesterase and cause delayed peripheral neuropathy. Paraoxon is an insecticide and will 
be described in detail in a later section. Following purification of the CHO supernatant  and 
the plant leaf extract using procainamide sepharose, rMaBChE molecules conjugated with 
polyetheleneglycol (PEG) using succinimidyl-propionate-activated methoxy-PEG-20K (SPA-
PEG-20K; Nektar Inc., Birmingham, AL) or Sunbright ME-200HS 20K PEG (NOF, Tokyo, 
Japan) (Chilukuri et al., 2008a; Cohen et al., 2001) to test the effects of PEGylation on enzyme 
plasma stability. Initially, the biochemical properties of both the unmodified and PEGylated 
forms of both monomeric and tetrameric rMaBChE were examined using DFP inhibition; 
bimolecular rate constants (ki  (  107) M-1 min-1) for inhibition of all the recombinants forms 
ranging from 2.58  - 2.23 (  107) M-1 min-1 which  were indistinguishable from the well 
characterized native HuBChE (2.29 +/- 0.1) and native MaBChE  (2.22 +/- 0.1) (data not 
shown).  
3.1 Inhibition and reactivation of plant derived CHO-derived and plant-derived rBChE 
by paraoxon 
The kinetics of inhibition of both plant-derived and CHO-derived rMaBChE by paraoxon 
were further examined as shown in Fig. 1A. At low paraoxon concentrations (0.01 and 
0.02uM), the reciprocal value of Et/Et,0 was highly correlated with the reaction time; the 
reaction rate constant of plant-derived rMaBChE at 0.01uM paraoxon being slightly faster 
than that of CHO-derived MaBChE (0.035 M-1min-1 vs 0.022 M-1min-1 respectively). These 
values follow the simple 2nd-order (reciprocal) model.  
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Fig. 1. Inhibition kinetics of plant- and CHO-derived* rMaBChE by different concentrations 
of paraoxon (0.01uM - 0.10uM) A: Percent inhibition of BChE by paraoxon. (Percent BChE 
activity was obtained by dividing the BChE activity with paraoxon at each time point with 
control BChE activity at the same time point. B: Reciprocal plot of BChE inhibition by 
paraoxon. 
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3.2 Reactivation of paraoxon-inhibited plant-derived rMaBChE by 2-PAM 
Since a 1 hour incubation of 0.016 uM plant-derived MaBChE (1.2U/ml) with 0.02uM 
paraoxon resulted in 80-90% inhibition of the enyme (Fig. 1A), the same conditions 
(incubation of paraoxon with rMaBChE at a final enzyme concentration of 0.04-0.05uM), was 
used to prepare inhibited rMaBChE. Reactivation of inhibited rMaBChE was then initiated 
by adding different concentrations of 2-PAM (0.4mM-6.4mM) for various times (Fig.2). The 
kinetics of reactivation of paraoxon-inhibited CHO- and plant-derived rMaBChE were 
found to follow the simple first-order (mono-exponential) model. 
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Fig. 2. Reactivation kinetics of paraoxon inhibited plant- and CHO-derived MaBChE by 2-
PAM. A, C: Plant-derived MaBChE; B, D: CHO-derived MaBChE; A and B: Direct plot of the 
time course vs % reactivation; C and D: Semi-logarithmic plot of time course of reactivation. 
For inhibition controls, inhibited BChE was incubated with reaction buffer without 2-PAM. 
Triplicate BChE assays were performed at the times indicated.  
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The results indicate that both paraoxon-inhibited plant- and CHO-derived rMaBChE 
showed very similar patterns of reactivation by different concentrations of 2-PAM (Fig. 2A, 
2B) with nearly 100 % reactivation of each rMaBChE form being achieved by 24 hours at 
>1.60 mM 2-PAM; the kapp values of CHO-rMaBChE ranging from 0.0014 to 0.004 min-1 and 
plant-rMaBChE from 0.0013 to 0.0051 min-1 (Fig. 2C, 2D). The reactivation kapps at each 2-
PAM concentration was linear when plotted against 2-PAM concentration (mM) expressed 
logrithmically.  
4. In vivo testing of rBChE 
In the area of insecticide exposure/contamination, there is a high likelihood that 
agricultural workers or military personnel will be exposed multiple times during their 
lives and thus multiple prophylactic treatments must be considered a possibly. This is 
often problematic since administration of heterologous HuBChE into macaques or other 
species eg mice has been shown to generate anti-BChE antibody responses and rapidly 
eliminate enzyme on repeated injections (Matzke et al., 1999; Chiluluri et al., 2008b; Sun et 
al., 2009). Thus, in vivo retention times of exogenously administered recombinant proteins 
can only be accurately assessed using homologous systems (rMaBChE  macaques and 
rHuBChE  humans) in which antibodies or other immune responses are not induced. In 
this context, homologous BChE enzyme has been shown to have a long half-life (8-12 
days) with no adverse effects and no immunogenicity following either (i) transfusions of 
human plasma into humans (ii) daily administrations of partially purified  native 
HuBChE into humans for several weeks (Jenkins et al., 1967; Cascio et al., 1988) or (iii) 
injection of purified native MaBChhE or PEG-rMaBChE into macaques (MRT= 200-300 
h)(Rosenberg et al., 2002, 2010). These data are in contrast to exogenously administered 
heterologous HuBChE which displayed a rapid clearance in macaques (MRT = 33.7 h) 
(Raveh et al., 1989). While the choice of the animal model for PK, immunogenicity and 
efficacy testing is always important, the animal species utilized for the evaluation of an 
efficacious human cholinesterase bioscavenger is critical, since potential treatments 
against OP toxicity cannot be tested in humans and will require extensive testing  
in animal models and the Animal Rule (CFR 601.90 for biologics) for regulatory  
approval. 
4.1 Pharmacokinetics of clearance in rodent and macaque models 
Pharmacokinetic profiles following administration of biologics in many rodent and primate 
species are used to indicate the periods after administration that such biologics are likely to 
exhibit optimal benefit or protection. An efficacious therapeutic for preventing OP 
poisoning is a molecule that: (i) can bind and scavenge the OP before it reaches the targeted 
AChE in neuromuscular junctions and (ii) has the ability to remain at therapeutic levels in 
the blood for prolonged periods to counteract a known or impending OP exposure. The in 
vivo parameters generally used to assess PK performance after administration are mean 
retention time (MRT),  maximal concentration (Cmax), time to reach maximal concentration 
(Tmax), elimination half life (T1/2) and area under the plasma concentration curve 
extrapolated to infinity (AUC).  
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Generally pharmacokinetics of recombinant molecules differs considerably depending on 
the structure, glycoslyation, size, route of administration, immunogenicity, and animal 
model utilized. Interestingly, despite protein sequence identity, rBChE proteins, similar to 
many other recombinant biologics, have been shown to be rapidly cleared following 
injection (Saxena et al., 1998; Cohen et al., 2006) in contrast to the good plasma stability of 
native BChE. Thus, rBChE molecules  require post-translational modification to provide 
protection as therapeutic scavengers. A common means of increasing the radius of the target 
molecule permitting slower renal clearance and prolonging plasma retention is by PEG 
conjugation. This has been successfully used with proteins, peptides, oliogonucleotides and 
antibody fragments to improve pharmacokinetic and immunological profiles (Kang et al., 
2009). Accordingly, both monomeric and tetrameric forms of rMaBChE have been 
conjugated with 20KD PEG  (without interference of  in vitro biological properties)  and the 
pharmacokinetic profiles of the unmodified and PEG-conjugated rMaBChE forms compared 
in monkeys and mice (Rosenberg et al., 2010).  
Figure 3 shows the PK profiles in 24 monkeys following iv injection of 1.2 -3 mg/kg of 
unmodified or PEG-rMaBChE and illustrates several aspects of BChE clearance: (i) PEG-
rMaBChE exhibits good stability in the lower range of the native form; the hierarchy of 
clearance being native BChE ~ PEG-rMaBChE >>> unmodified monomeric rMaBChE > 
unmodified tetrameric rMaBChE. (ii) Surprisingly, five of the monkeys demonstrated 
unexpected dramatic decreases in BChE levels (shown in bold between days 150 and 230 
days post injection). In each case, these decreases always occurred immediately after the 
weekend treatment of the grass surrounding the animal facility and presumably resulted 
from exposure of the housed monkeys to insecticide; highlighting the unintentional 
consequences of routine insecticide use on plasma BChE activity and (iii) despite very poor 
retention of the unmodified monomeric rBChE, administration of the PEGylated monomeric 
rMaBChE showed overlapping pharmacokinetic parameters with the larger PEG-rMaBChE 
tetrameric form despite lack of oligomerization.  
Importantly, the extended circulatory retention afforded by PEG conjugation of rMaBChE in 
monkeys (injected iv) was not observed in mice (injected ip) where unmodified and 
modified monomeric and tetrameric rMaBChE all exhibited the same high MRT and T1/2 
(Rosenberg et al., 2010). This indicates that, depending on the parameter measured, the 
mouse model does not accurately predict the outcome in monkeys with MRT and T1/2 
values appearing to be less predictive indicators of circulatory stability in macaques than 
parameters such as AUC and Cmax. Similar differential pharmacokinetic behaviour was 
observed following the administration of recombinant rhesus (Rh) and HuAChE in mice 
and monkeys (Cohen et al., 2004).  
These studies highlight the potential problems inherent in choosing an animal model to test 
human biologics. Notwithstanding the differences in pharmacokinetic behaviour of the 
same protein in different species and the high potential for immunogenicity in rodents due 
to the evolutionary distance between rodents and humans, other influences may also play a 
role in the circulatory stability of proteins following even the first injections into 
heterologous species. Table 2 shows the pharmacokinetic parameters (MRT, Cmax, Tmax, 
T1/2 and AUC ) following injection of different forms of BChE into several different animal 
species determined from the time course curve of blood BChE concentrations and using a 
Windows-based program for non-compartmental analysis. Several conclusions can be made.  
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Fig. 3. Pharmacokinetics of clearance following iv injection of 1.2 - 3.0 mg/kg rMaBChE into 
24 monkeys. Each line represents a single monkey. Different forms of rMaBChE were used 
except for 4 macaques receiving native BChE. 
For example, while the Cmax following first injections appear to be similar in any animal 
model at comparable doses, the AUC, MRT and T1/2 are often significantly higher in 
homologous systems (e.g. PEG-rMaBChE into macaques and native mouse (Mo) BChE into 
mice) than heterologous injections (native HuBChE into monkeys or mice or PEG-rHuBChE 
into monkeys). This indicates that heterologous proteins, even when PEGylated and given at 
a time when anti-BChE titers are absent or low, appear to be eliminated faster than 
homologous proteins suggesting that pharmacokinetic parameters are less than optimal in 
all heterologous systems.  
It should also be noted, that while PEG conjugation markedly improves the 
pharmacokinetic profile of therapeutic rMaBChE and other biologics, effects relating to 
immunogenicity have been mixed. Thus, reduced immunogenicity has been observed 
following PEGylation of enzymes, cytokines and hormones, while administration of 
PEGylated interferon-1a to monkeys actually resulted in increased immunogenicity 
(Pepinsky et al., 2001). In the case of rHuBChE produced in HEK-293 cells, PEGylation failed 
to eliminate immunogenicity in mice as demonstrated by the rapid clearance of a repeat 
100U injection of (heterologous) PEG-rHuBChE, coincident with induction of high levels of 
serum anti-BChE antibody ( Sun et al., 2009). Likewise, when tested in a sandwich ELISA, 
the presence of 4–7 PEG molecules per rMaBChE monomer did not prevent the binding of 
BChE epitopes to either an anti-BChE MAb or a polyclonal rabbit anti-BChE antibody when 
antigen concentrations were increased to as little as 4–8 U/ml (Rosenberg et al., 2010) which, 
as mentioned above,  is in the range of BChE in normal plasma. These studies raise the 
question whether chemical modification by PEG will be able to mask any “foreign” rBChE 
epitopes, such as non-human glycans, sufficient to prevent humoral immune responses and 
also highlights the importance of using homologous animal models to perform in vivo PK, 
immunogenicity and efficacy testing. 
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BChE
Dose
[Units, mg, mg/kg]
Animal Route
MRT
(hr)
AUC
(U/ml.h)
Cmax
(U/ml)
Tmax
(hr)
T1/2 
(hr)
natHuBChE (Raveh,1997) 11.5 mg (8,000 U) Monkey iv 33 710
natHuBChE 11.5 mg (8,000 U) Monkey im 582 16.2 9.5
natHuBChE (Lenz,2005) 5.25 mg/kg (12,000 U) Monkey im 2576 21 9.27 79.3
8.75 mg/kg (20,000 U) Monkey im 3822 33 10.3 73.5
natHuBChE (Sun, 2005) 34 mg/kg (30,000 U) Monkey iv 73 16,538 222 0 37
natHuBChE (Sun, 2009) 100 U Mouse im 48 1,300 19 21
natMaBChE * 100 U Mouse im 73 2,500 25 24
BChE
Dose
[Units, mg, mg/kg]
Animal Route
MRT
(hr)
AUC
(U/ml.h)
Cmax
(U/ml)
Tmax
(hr)
T1/2 
(hr)
natMaBChE * 3 -5 mg/kg (7,000 U) Monkey iv 191
(Rosenbberg, 2002) 1.3 - 1.65 mg/kg (3,000 U) Monkey iv 50
natMaBChE (unpub)* 1.8 mg/kg Monkey iv 142 2950 27
1.8 mg/kg Monkey iv 142 4010 37
natMaBChE* 2.9 mg/kg Monkey iv 224 4431 38 143
(Rosenberg, 2010) 2.9 mg/kg Monkey iv 307 4299 40 126
1.9 mg/kg Monkey iv 200 2097 26 157
PEG-rMaBChE* 2.9 mg/kg Monkey iv 168 2141 33 112
(Rosenberg, 2010) 2.9 mg/kg Monkey iv 223 3312 39 85
1.9 mg/kg Monkey iv 134 1724 24 97
PEG-rMaBChE (unpub)* 3.0 mg/kg Monkey iv 4359 51
PEG-rHuBChE (unpub)* 3.0 mg/kg Monkey iv 1101 40
Human and Mouse BChE
Monkey BChE
 
MRT: mean retention time, Cmax: maximal concentration, Tmax: time to reach maximal concentration, 
T1/2: elimination half life, AUC: area under the plasma concentration curve extrapolated to infinity. 
nat: native, Mon: monomeric, Tet: tetramer. 
Table 2. Pharmacokinetic parameters of different forms of BChE in homologous* and 
heterologous systems. 
4.2 The role of glycosylation and oligomerization on pharmacokinetics 
The BChE molecule is a soluble protein, protected from proteolysis by a heavy sugar coating 
from nine N-linked glycans (Li et al., 2008). N-glycosylation is one of the major post-
translational modifications of proteins and can be critical to their bioavailability. 
Importantly, while the first steps in the N-glycosylation pathway, leading to the formation 
of oligomannosidic structures, are conserved in plants and animals, the final steps in the 
formation of complex N-glycans may differ with the expression system used. Thus, in 
contrast to native HuBChE molecules which have highly sialylated bi- and triantennary type 
glycans (Saxena et al., 1998; Kolarich et al. 2008) containing the N-acetyl neuraminic acid 
(NANA, NeuAc) form of sialic acid (Varki, 2001), rHuBChE molecules may exhibit under-
sialyated or immunogenic non-human glycan structures that accelerate in vivo clearance 
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due to rapid uptake by asialoglycoprotein and mannose receptors in the liver or by  
antibody-mediated mechanisms (Park et al., 2005). For example, CHO cells produce 
recombinant proteins which contain human-like glycans that may be undersialyted, 
compared to those produced in livestock systems which append the non-human galactose-
-1,3-galactose and the N-glycolyl neuraminic (NGNA, NeuGc) form of sialic acid (Chung 
et al., 2008; Diaz et al., 2009) and those produced in plants which are non-sialylated and 
append the non-human -1,2 xylose and -1,3 fucose containing glycans (Altmann, 2007).  
The relationship between sialic acid levels and oligomerization of recombinant molecules 
with their circulatory longevity has been extensively studied. For example, administration to 
mice of recombinant bovine and rhesus acetylcholinesterase (rBoAChE, rRhAChE) as well 
as plant-derived rHuBChE have supported the idea that pharmacokinetic behaviour is 
governed by hierarchical rules (Kronman et al., 2000); efficient enzyme tetramerization and 
high sialic acid occupancy both being required for optimal plasma retention. However, 
other data from monkey and mice studies do not closely obey these classical rules for 
circulatory retention. For example: (i) the requirement for tetramerization of rAChE 
molecules was less important when performed in macaques rather than mice (Cohen et al., 
2004) (ii) CHO-derived monomeric PEG-rMaBChE resulted in high MRT when injected into 
in monkeys (Fig.3, Rosenberg et al., 2010) and (iii) the MRT and T1/2 of unmodified and 
PEG-modified monomeric rMaBChE were both unexpectedly high following injection into 
mice; PEG-conjugation offering no significant advantages.  
While the short lived circulatory retention of asialylated BChE attests to the importance of 
sialylation in retention/clearance,  the degree to which silaic acid occupancy is required 
does not always seem straight forward. Thus, although the rapid clearance of monomeric 
(13% non-silayted) and tetrameric (25% nonsialyted) rMaBChE in monkeys, compared to the 
native or PEGylated forms, has been thought to result from undersialylation, glycan analysis 
by MALDI-TOF of the highly stable native HuBChE and MaBChE proteins indicates that 
these also contain a significant percentage of nonsialyted or undersilayted proteins. For 
example, native HuBChE contains 23% monosialyted glycans (99.9% NANA) and a 
significant percentage of non-sialyted glycans (Kolarich et al., 2008) while native MaBChE is 
comprised of 21.3% non-sialayted glycans and 21.8% monosialylated glycans ( 99.9% 
NGNA) (Rosenberg, unp. data). This means that heterologous animal models  invariably 
involve the administration of native or CHO-derived human proteins containing NANA 
into animals containing the NGNA form of sialic acid (monkeys, rodents). These findings 
showing either high percentages of undersialylated glycans in the stable native proteins and 
those showing lower pharmacokinetic parameters following heterologous injections, raise 
the interesting question as to whether the type of sialic acid type as well as the degree of 
sialic acid occupancy may determine the rate of clearance of recombinant glycoproteins.  
It is also important to note that recent engineering of different expression systems is now 
permitting the production of glycoproteins with human-like glycans. For example, while the 
inability to perform appropriate N-glycosylation has been a major limitation of plants as 
expression systems, these are being overcome by new approaches involving the generation 
of knockout or knockdown plants that: (i) completely lack xylosyl transferase (XylT) and 
fucosyl transferase (FucT) activity (Strasser et al., 2004) and accumulate high amounts of 
human-like N-glycan structures that contain no 1,2-xylose or core a1,3-fucose (ii)  lack 
complex N-glycans resulting from the inactivity of N-acetlyglucosaminyltransferase 1 
(GnT1) (Strasser et al, 2005; Wenderoth & von Schaewen, 2000) and (iii) contain glycans 
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terminating in sialic acid (Paccalet et al., 2007; Castilho et al., 2010). In addition, different 
glycoforms of plant derived proteins can be generated by protein targeting to different 
compartments (i) cytosol (aglycosylated) (ii) ER (high mannose) or (iii) secreted into the 
apoplast (complex) (Stoger et al., 2005)  
4.3 Effects of the route of administration on pharmacokinetics  
As mentioned, delivery of PEG-rBChE as a pre-exposure modality is disadvantaged by its 
large size and a 1:1 stoichiometry between the enzyme and OP requiring high doses due to 
the high LD50 of many insecticides (ug-mg/kg levels). The route of systemic delivery of high 
doses of native BChE (MW~350KDa) and tetrameric PEG-rMaBChE (MW>800KDa) will 
determine the pharmacokinetics (PK) of clearance and is critical to efficacy and safety. 
Currently very little monkey data exists on the delivery of a stoichiometrically equivalent 
dose of PEG-rBChE calculated to protect against a known LD50 of a toxic OP insecticide. 
Although immediate release requiring intravenous (iv) injection may be necessary in certain 
high threat situations, these are usually impractical in the field. Needleless cutaneous 
delivery via the dermis and epidermis (chemical mediators, electroporation) appear quite 
promising, but are unlikely to deliver high doses. Thus, self-administered transdermal 
injections through the skin either by subcutaneous (sc) or intramuscular (im) routes have 
been the approaches most commonly used; virtually all human vaccines currently on the 
market being administered via these routes. Traditionally, autoinjectors, devices for im 
delivery of a self administered single dose of a drug are used in the military to protect 
personnel from chemical warfare agents and are currently used to deliver morphine for pain 
and atropine, diazepam and 2-PAM-Cl for first-aid against nerve agents. For this reason, 
most animal protection studies with OP bioscavengers have routinely been delivered im to 
rodents (Lenz et al., 2005; Mumford et al, 2010; Saxena, et al., 2011). 
Despite all the pharmacokinetics data generated using im and sc routes of delivery of many 
drugs and biologics, little is known about the factors that govern the rate and extent of 
protein absorption from the injection site and the role of the lymphatic system in the 
transport of large molecules to the systemic circulation. With smaller molecules, the time to 
maximal concentration is usually shorter following im injections compared to sc injections 
where absorption is slow and prolonged and accounts for the lag in entering the blood. 
However with larger therapeutic molecules (MW>16KDa), the lymphatics are thought by 
some groups to be the primary route of absorption from sc (and im) injection sites. Large 
molecules are thought to exit the interstitium via cleft like openings into the lymph and 
enter the systemic circulation via the thoracic duct (Supersaxo et al., 1990; Porter et al., 2001; 
McLennan et L., 2006). To assess the effects of different routes of delivery, pharmacokinetic 
behaviour using different doses of PEG-rMaBChE tetrameric molecules was compared in 
monkeys following im and sc injections.  
4.3.1 Intramuscular delivery of PEG-rMaBChE 
Four monkeys each received an im injection of either 2.5 or 3 mg/kg of PEG-rMaBChE. As 
shown in Fig. 4, unlike the delivery of the smaller native HuBChE which appear to behave 
uniformly following im injection (Lenz et al., 2005), the much larger PEG-conjugated form 
exhibits very variable results when delivered into the muscle with Tmax values in the 4 
macaques having values of 8, 24, 48 and 48 hr respectively; the 8-hour peak looking more 
like an iv injection than an im injection. It is not clear whether this more rapid exit from the 
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muscle injection site into the blood reflects a more vascularised muscle or whether im 
delivery has more potential to damage blood vessels and promote faster draining. It is clear 
however that delivery of large doses of a therapeutic such as PEG-rHuBChE will require 
many im injections to achieve required peak values and will increase the likelihood of 
targeting a blood vessel. The stoichiometric dose of BChE required to protect humans 
against 2 LD50 of soman has been considered to be 3 mg/kgm (200 mg/70 kg); the antidotal 
efficacy of BChE being contingent upon both the rate of OP detoxification and its levels in 
blood (Raveh, 1997; Ashani & Pistinner, 2004). It would be unlikely that Cmax values (20 
and 23 U/ml at 3 mg/kg and 17 and 10 U/kg at 2.5 mg/kg) following im administration 
would be sufficient for protection. In addition, the variable times of peak enzyme make it 
difficult to choose a time for prophylactic dosing. 
4.3.2 Subcutaneous delivery of PEG-rMaBChE 
Extensive pharmacokinetics have been performed on many well known biologics in 
monkeys and humans, either PEGylated or unmodified, using the sc routes of delivery 
(Boelaert et al., 1989; Ramakrishnan et al., 2003; Heatherington et al., 2001; Radwanski et al., 
1987; Mager et al., 2005), although extrapolation from these studies may be problematic 
because all used considerably smaller molecules than native or PEG-rBChE. Generally, sc 
injections have been the delivery route of choice for compounds with limited oral 
bioavailability, as a means of modifying or extending the release profiles of these molecules, 
or as a means of delivering drugs that require large quantities (Yang, 2003) since larger 
volumes may be injected. In one case, a highly concentrated form of a therapeutic requiring 
large doses for its effects has be prepared as a crystalline and successfully delivered sc in a 
small volume (Yang et al. 2003). 
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Fig. 4. Pharmacokinetic profiles of PEG-rMaBChE delivered by im injection. Four monkeys 
were injected into the thigh muscles using a 1-ml syringe. 
Figure 5 shows the pharmacokinetic profiles following sc delivery of the tetrameric PEG-
rMaBChE at 2.5, 3 and 5 mg/kg. Tmax values were all consistently ~48 hrs, regardless of the 
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dose. However, while Cmax was generally associated with dose, there was a good deal of 
overlap between the 3 mg/kg and 5mg/kg doses; the larger doses being retained at higher 
levels in the blood for many days. This once again raises the question as to whether a high 
dose of very large molecules can leave the site of the sc injection and enter the blood at 
levels required for protection. By contrast 3 mg/kg delivered iv reaches a peak of >50 U/ml. 
It is important to note that despite the apparent low bioavailability of sc administered 
proteins compared to those given intravenously (17-65%), sc delivery often produces 
equivalent efficacy to iv administration and is assumed to be due to prolonged absorption 
leading to reduced receptor saturation. 
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Fig. 5. Pharmacokinetics of PEG-rMaBChE delivered by sc injection. Eight monkeys were 
injected with the doses indicated  in 2-4 ml sc between the shoulder blades. 
A direct comparison of the pharmacokinetic parameters following im versus sc injections of 
4 monkeys at does of 2.5 mg/kg and 3 mg/kg is shown in Table 3 and indicates that the im 
and sc values are quite similar. Overall, the results indicate that for a very high MW protein 
such as PEG-rMaBChE or PEG-rHuBChE, neither im or sc administrarion are optimal to 
achieve good plasma retention with high PK parameters. For this reason, a different non-
parenteral route of delivery via the lung, where the high MW becomes an advantage, is now 
the choice route of delivery. 
 
Parameters Subcutaneous injection Intramuscular injection 
 Four individual monkeys Four individual monkeys 
MRT (h) 62.23   90.12   110.2    73.4 49.37    60.99    58.6     108.0 
T1/2 (h) 25.2     42.3     77.8     37.8 23.3    19.4   24.0    58.7 
Cmax (U/ml) 19.6     18.3     12.3     11.0 23.1     20.3      16.5    9.8 
AUC (U/ml·h) 1706     1856    1489   1128 1762    1675     1089      1367 
Table 3. Comparison of the pharmacokinetics parameters four following sc and im injections 
performed in parallel. 
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4.4 Protection studies with PEG-rMaBChE 
Many studies have demonstrated efficacy of native HuBChE, both pre-and post–exposure, 
in rodents and monkeys to protect against OP nerve agents delivered by sc injection, iv 
injection or vapour. (Lenz et al., 2005; Sun et al., 2008; Saxena et al., 2011;  Mumford et al, 
2010). Protection has also been shown in mice and guinea pigs using PEG-rBChE produced 
in goat and plants (Huang et al. 2007, Geyer et al., 2010). However, very few studies have 
utilized the non-human primate monkey model for assessing insecticide toxicity and none 
have used respiratory exposure. 
Two types of protection studies using different routes of delivery are currently being 
performed to assess the ability of BChE to protect against toxicity resulting from exposure to 
the insecticide  paraoxon.  
1. Aerosolized PEG-rMaBChE 1 hr prior to aerosolized paraoxon exposure.  
2. Intravenous delivery of PEG-rMaBChE 1 hr prior to sc delivery of paraoxon. 
4.4.1 Paraoxon 
The majority of OP insecticides are lipophilic, not ionised, and are absorbed rapidly 
following inhalation or ingestion (Vale, 1998). Dermal absorption is slower and can be 
prevented by removing clothes and bathing, but severe poisoning may still ensue if 
exposure is prolonged. Respiratory pesticide exposure by inhalation of powders, airborne 
droplets or vapours is particularly hazardous because pesticide particles can quickly enter 
the bloodstream via the lungs and cause serious damage. Under low pressure, droplet size is 
too large to remain airborne. However, when high pressure, ultra low volume application 
(ULV) or fogging equipment is used for agricultural purposes, respiratory exposure is 
increased due to the production of mist- or fog-size particles, which can be carried on air 
currents for a considerable distance (Armed Forces Pest Management Board Technical 
Guide No. 13). Small children are highly vulnerable because they breathe in greater volumes 
of air, relative to their body weight, than adults.  
 
 
 
 
Fig. 6. Chemical structure of parathion and paraoxon. 
Paraoxon is the active metabolite of the inactive parathion (Fig. 6) produced by a sulfur-for-
oxygen substitution carried out predominantly in the liver by the mixed-function oxidases 
(Dauterman, 1971). It was chosen for these studies because it inhibits AChE, BChE and 
carboxylesterase (Levine, 2006), it has a relatively low LD50, and low volatility and stability 
in aqueous solution. Parathion has probably been responsible for more cases of accidental 
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poisoning and death than any other OP insecticide (Lotti & Moretto, 2005) and was recently 
phased out of use in the US. In humans, parathion is absorbed via skin, mucous membranes, 
and orally and is rapidly metabolized to paraoxon which can result in headaches, 
convulsions, poor vision, vomiting, abdominal pain, severe diarrhea, unconsciousness, 
tremor, dyspnea and finally lung-edema as well as respiratory arrest. Symptoms of severe 
poisoning are known to last for extended periods of time, sometimes months. Additionally, 
peripheral neuropathy including paralysis is noticed as late sequelae after recovery from 
acute intoxication (http://extoxnet.orst.edu/pips/parathio.htm). Parathion has been 
extensively used for committing suicide and potentially for the deliberate killing of people. 
4.4.2 Aerosolized PEG-rMaBChE protection against aerosolized paraoxon exposure  
As an alternative to delivering high doses of a large molecule into the systemic circulation 
by sc or im routes, studies are currently being performed using aerosol therapy for 
delivering rBChE directly to the lung in order to create an effective “pulmonary bioshield” 
that will detoxify incoming inhaled insecticide in situ and prevent or reduce respiratory 
toxicity. This takes advantage of the large size of the molecule which will be retained in the 
lung due to its inability to pass through the lung endothelium into the blood. In this context, 
inhalation serves as a major means of intoxication because of rapid accesses of the OP to the 
blood. An efficient pre-exposure pulmonary therapeutic in the form of aerosolized PEG-
rBChE could be delivered before a known use/release of insecticides and prevent the lung 
damage and delayed neuropathy often associated with exposure, while reducing the need 
for post-exposure atropine and oximes. 
Maxwell et al. (2006) have recently shown that for OP compounds (including the 
insecticides paraoxon, DFP and dichlorvos) the primary mechanism of in vivo toxicity is the 
inhibition of AChE and the residual unexplained variation in OP toxicity represents <10% of 
the total variation in toxicity. Almost all of the variation in the LD50 of OP compounds in 
rats was explained by the variation in their in vitro rate constants for inhibition of AChE. 
Thus, to develop a paraoxon/monkey  animal model for aerosolized insecticide exposure 
and to avoid unnecessary stressing and killing of monkeys in developing the model, the 
dose of aerosolized paraoxon required to achieve a ~50% inhibition of RBC AChE and 
serum BChE has been used initially as a readout for toxicity and a basis from which to 
analyse protection by CHO-derived rMaBChE. Thus, paraoxon which is not neutralized in 
the lung will enter the blood and can be measured by the inhibition of AChE and BChE 
activity in lysed whole blood using using a modified assay (Ellman et al, 1961) with 5,5'-
dithiobis(2-nitrobenzoic acid), the substrate acetyl-thiocholine (ATC) and 20uM etho-
propazine to inhibit BChE activity. 
Initially, the dose of aerosolized paraoxon required to produce ~50% inhibition of red blood 
cell (RBC) AChE and BChE in the circulation was first determined in mice prior to the 
macaque studies. The LD50 of paraoxon in rodents has been established using oral, 
percutaneous (pc) and subcutaneous (sc) routes (mice: 760 ug/kg orally; 270 - 800 ug/kg sc 
and for rats: 1800 ug/kg orally and 200 - 430 sc (reviewed in Levine, 2006; Villa et al., 2007). 
Milatovic et al. (1996) showed that a single acute injection of 0.09, 0.12, or 0.19 mg/kg 
paraoxon in rats, representing 40% LD50, 52% LD50 and 83% LD50 respectively, did not 
produce signs of cholinergic hyperactively. In the present study, the effective dose of 
aerosolized paraoxon resulting in 50% inhibition in mice was found to be 150-180 ug/kg 
which is less toxic than the parenteral route. In addition, aerosolized BChE given 24 hr prior 
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to the paraoxon significantly reduced the AChE inhibition (our unpub. data). Rodents 
contain a high endogenous levels of CaE, another stoichiometric OP scavenger (Dirnhuber 
et al. 1979) and are known to be ~10-fold less sensitive to soman than non-human primates 
(Maxwell et al., 2006). Accordingly, a dose of 15 ug/kg of aerosolized paraoxon has been 
shown to result in 50-60% RBC AChE inhibition and preliminary data indicate that PEG-
rMaBChE , delivered as a pre-exposure aerosol one hour prior to exposure, can totally 
reduce this inhibition in a dose –dependent manner. 
4.4.3 Intravenous PEG-rMaBChE protection against subcutaneous paraoxon exposure  
These studies are being formed to compare routes of delivery with efficacy of protection and 
indicate that while paraoxon delivered sc is also more toxic than as an aerosol, complete 
protection can be achieved by PEG-rMaBChE pretreatment. 
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